Search

Displaying results 71 - 80 of 359 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    It was approved in Europe in February 2015, and in the United States on March 21, 2017.

  2. Drug

    Protokylol

    go.drugbank.com/drugs/DB06814
    ApprovedVet approved

    Protokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.

  3. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  4. Drug

    Brimonidine

    go.drugbank.com/drugs/DB00484
    ApprovedInvestigational

    Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 ...

  5. Drug

    Flubendazole

    go.drugbank.com/drugs/DB08974
    ApprovedInvestigationalWithdrawn

    It is available OTC in Europe.

  6. Drug

    Talc

    go.drugbank.com/drugs/DB09511
    ApprovedInvestigational

    Talc is a mineral composed primarily of magnesium, silicon and oxygen. It is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. Talc helps absorb moisture, fres...

  7. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. … [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018.

  9. Drug

    Sultopride

    go.drugbank.com/drugs/DB13273
    Approved

    Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics [L5626].

  10. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Demecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the...